

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date:28.05.2022

The Head- Listing Compliance
BSE Limited
PhirozeJeejeebhoyTowers
Dalal Street
Mumbai-400001

Scrip Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, i.e. **Saturday, 28th day of May, 2022**(commenced at **01.00 P.M.** and concluded at **4:30 P.M** at Registered office of the Company at 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, has inter alia approved and passed the following resolutions:

1. The **Audited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended March 31, 2022.**(Copy enclosed)**
2. Took note of the **Audit Report** as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter and year ended March 31, 2022.**(Copy enclosed)**
3. The declaration of **unmodified opinion on Auditor's report** on annual financial result for the quarter and year ended March 31, 2022.**(Copy Enclosed)**
4. The Board has appointed **M/s Ojha & Associates**, Practicing Company Secretaries, as Secretarial Auditor for the financial year 2021-22.

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is attached as **Annexure A**.

5. Declaration of **Non-Applicability** of Compliance with Statement of Deviation(s) or Variation(s) as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter ended March 31, 2022. **(Copy Enclosed)**

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

6. Took note of the **Non applicability** of Disclosure of Related Party Transactions on a consolidated basis as required under Regulation 23(9) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for half year ended on 31st March, 2022.
(Copy Enclosed)

Kindly take the above information on your records.

Thanking you,

For Raymed Labs Limited

AJAI
GOYAL

Ajai Goyal

Whole Time Director

DIN: 02636418

Digitally signed by
AJAI GOYAL
Date: 2022.05.28
16:36:45 +05'30'

Place: Noida

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Annexure-A

Sr. No.	Particulars	Details
1.	Reason for Change Viz., appointment, resignation, removal, death or otherwise	NA
2.	Date of Appointment	28.05.2022
3.	Term of Appointment	For the Financial Year 2021-22
4.	Brief Profile	M/s. Ojha & Associates is a Practicing Company Secretaries firm in Kanpur, duly registered with The Institute of Company Secretarial of India (ICSI) holding an experience of more than nine years with Certificate of Practice No. 10790. The Firm deals in the areas of Corporate Laws, Corporate Governance, Legal, Statutory Matters and other matters connected with various authorities like RBI, MCA, SEBI, NCLT, FEMA etc.

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 28.05.2022

The Head- Listing Compliance
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001

Scrip Code: 531207

Sub: Declaration on Audit Report for the year ended 31st March, 2022

Dear Sir/Madam,

We hereby declare, on behalf of **Raymed Labs Limited** that Audit report in respect to Annual Standalone Audited financial Results for the period ended 31st March, 2022 submitted by **M/s. A Kay Mehra & Co., Chartered Accountants**, Statutory Auditor of the Company is with **unmodified opinion** of the Statutory Auditor.

Thanking you,

For Raymed Labs Limited

AJAI
GOYAL
Digitally signed by
AJAI GOYAL
Date: 2022.05.28
16:39:28 +05'30'

Ajai Goyal
Whole Time Director
DIN: 02636418

Place: Noida



INDEPENDENT AUDITORS' REPORT ON STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2022

To,
**THE BOARD OF DIRECTORS OF
RAYMED LABS LIMITED
103 EMPEROR 1, SUPERTECH EMERALD COURT,
SECTOR 93A, NOIDA - 201304,**

Report on the audit of the Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date financial results of RAYMED LABS LIMITED ("**the Company**") for the quarter ended March 31, 2022 and for the year ended March 31, 2022 ("**Statement**"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("**Regulation**").

In our opinion and to the best of our information and according to the explanations given to us, these Financial Results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard;

and

- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2022 and for the year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("**the Act**"). Our responsibilities under those Standards are further described in the "*Auditor's Responsibilities for the Audit of the Financial Results*" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Director Responsibilities for the Financial Results

These quarterly financial results as well as the year-to-date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other

Depada SJP



A. KAY. MEHRA & CO.

CHARTERED ACCOUNTANTS

2470 (BASEMENT), HUDSON LINE,
G.T.B. NAGAR, DELHI-110009
NEAR GTB NAGAR METRO STATION,
Ph. No.: 011- 42461274, 9891295255
E- Mail: akmca1969@gmail.com
Website: www.akmca.in

comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to





2470 (BASEMENT), HUDSON LINE,
G.T.B. NAGAR, DELHI-110009
NEAR GTB NAGAR METRO STATION,
Ph. No.: 011- 42461274, 9891295255
E- Mail: akmca1969@gmail.com
Website: www.akmca.in

continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter (if any)

We draw attention to:

- (1) During the year Company's administrative & other general expenses are paid by Ajay Goyal (Director) on behalf of the company.
- (2) Company has not paid BSE Listing fee since last two Financial Years i.e.(FY 2020-21 & 2021-22)
- (3) Material Uncertainty Related to Going Concern
The Company is not doing any business operations from past more than three years and neither searching for any revenue-generating opportunity during the year.
- (4) Debtors, Creditors, Loan & Advances balance are subjected to confirmation.

Our opinion is not modified in respect of this matter.

The Statement includes the results for the Quarter ended March 31, 2022 being the balancing figure between audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our report is not modified in respect of these matters.

For A. Kay. Mehra & Co.

Chartered Accountants

FRN: (050004C)

Deepak Suneja

CA Deepak Suneja

Membership No- 501957

Date: 28-May-2022

UDIN- 22501957AJUQXB1318



Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2022

Amt. (In Lakhs)

Particulars	Quarter Ended			Year Ended	
	31st March, 2022 (Audited)	31st Dec, 2021 (Unaudited)	31st March, 2021 (Audited)	31st March, 2022 (Audited)	31st March, 2021 (Audited)
I. Revenue from Operations	0.00	0.00	0.00	0.00	0
II. Other Income	0.00	0.00	0.00	0.00	0.66
III. Total Income (I +II)	0.00	0.00	0.00	0.00	0.66
IV. Expenses					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.65	0.95	0.90	2.82	2.00
Finance Costs	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	0.13	0.13	0.14	0.52	0.57
Other Expenses	3.61	0.55	3.75	4.87	4.97
Total Expenses (IV)	4.39	1.63	4.79	8.21	7.54
V. Profit/(Loss) before exceptional items and tax (III- IV)	-4.39	-1.63	-4.79	-8.21	-6.88
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	-4.39	-1.63	-4.79	-8.21	-6.88
VIII. Tax Expense					
(1) Current tax	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-4.39	-1.63	-4.79	-8.21	-6.88
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-4.39	-1.63	-4.79	-8.21	-6.88
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)	-4.39	-1.63	-4.79	-8.21	-6.88
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)					
XVI. Paid up Equity Share Capital (Face Value of Rs. ___ Each)	427.35	427.35	427.35	427.35	427.35
XVII. Other Equity				-640.85	-632.64
XIX. Earnings per equity share (for continuing operation):					
(1) Basic	-0.1028	-0.0382	-0.0112	-0.0192	-0.0161
(2) Diluted	-0.1028	-0.0382	-0.0112	-0.0192	-0.0161
XX. Earnings per equity share (for discontinued operation):					
(1) Basic	0.000	0.000	0.00	0.000	0.00
(2) Diluted	0.000	0.000	0.00	0.000	0.00
XXI. Earnings per equity share (for discontinued & continuing operations)					
(1) Basic	-0.1028	-0.0382	-0.0112	-0.0192	-0.0161
(2) Diluted	-0.1028	-0.0382	-0.0112	-0.0192	-0.0161

- Notes:**
- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 28th, May 2022. The Statutory Auditors have carried out their audit for the above results.
 - The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
 - The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
 - The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
 - As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.
 - The figures of the last quarters are the balancing figures between audited figures in respect of the full financial year up to March 31, 2022 and March 31, 2021 and the unaudited published year-to-date figures up to December 31, 2021 being the date of the end of the third quarter of the respective financial years which were subjected to limited review.

For Raymed Labs Limited

AJAI GOYAL
 Digitally signed
 by AJAI GOYAL
 Date: 2022.05.28
 16:32:35 +05'30'

(Ajai Goyal)
 Whole time Director
 DIN : 02636418

Date: 28.05.2022
 Place :Noida

Raymed Labs Limited
Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304,
Uttar Pradesh, CIN: L24111UP1992PLC014240
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com,
Tel: 0120-2426900, 9412700300

Statement of Audited Standalone and Consolidated Assets and Liabilities for the year ended March 31, 2022

Particulars	Amount in Lakhs.	
	As at 31st March, 2022	As at 31st March, 2021
	(Audited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	15.56	16.09
(b) Capital Work in Progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.03	0.03
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financials Assets-		
(i) Investments	0.00	0.00
(ii) Trade Receivables	0.00	0.00
(iii) Loans	0.00	0.00
(iv) Other (to be specified)	0.00	0.00
(i) Deferred tax assets (net)	0.00	0.00
(j) Other non-current assets	0.00	0.00
Current Assets		
(a) Inventories	0.00	0.00
(b) Financials Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	2.49	2.49
(iii) Cash and cash equivalents	0.05	0.15
(iv) Bank Balance other than (iii) above	0.02	0.03
(v) Loans	6.10	6.10
(vi) Others (to be specified)	0.00	0.00
(c) Current tax Assets	0.00	0.00
(d) Other current Assets	0.28	0.28
TOTAL ASSETS	24.53	25.16
EQUITY AND LIABILITIES		
Equity-		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	-640.85	-632.64
Liabilities		
Non -Current liabilities		
(a) Financials Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payable	0.00	0.00
(iii) Other Financial liabilities (other than specified in item (b) to be specified)	220.74	0.00
(b) Provisions	0.00	0.00
(c) Deffered Tax Liabilites (net)	0.00	0.00
(d) Other Non-Current Liabilities	0.00	0.00
Current Liabilities		
(a) Financials Liabilities		
(i) Borrowings	0.00	216.33
(ii) Trade Payables	5.32	5.60
(iii) Other Financial liabilities (other than specified in item (c) to be specified)	5.00	5.00
(b) Other current liabilities	0.49	0.28
(c) provisions	6.48	3.24
(d) Current Tax Liabilites	0.00	0.00
TOTAL EQUITY AND LIABILITIES	24.53	25.16

For Raymed Labs Limited

AJAI GOYAL
Digitally signed by
AJAI GOYAL
Date: 2022.05.28
16:31:00 +05'30'

(Ajai Goyal)
Whole time Director
DIN : 02636418

Date: 28.05.2022
Place : Noida

Raymed Labs Limited
Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304,
Uttar Pradesh, CIN: L24111UP1992PLC014240
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com,
Tel: 0120-2426900, 9412700300

AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

<i>Particulars</i>	Amount in Lakh	
	Year ended March 31, 2022 (01.04.2021 to 31.03.2022) (Audited)	Year ended March 31, 2021 (01.04.2020 to 31.03.2021) (Audited)
Cash flow from Operating Activities		
Profit Before Tax	-8.21	-6.88
Adjustments for		
Adjustments for finance costs	0	0
Adjustments for decrease (increase) in inventories	0	0
Adjustments for decrease (increase) in trade receivables, current	0	0
Adjustments for decrease (increase) in trade receivables, non-current	0	0
Adjustments for decrease (increase) in other current assets	0	0
Adjustments for other financial assets, non-current	0	0
Adjustments for other financial assets, current	0	0
Adjustments for other bank balances	0	0
Adjustments for increase (decrease) in trade payables, current	-0.28	0.06
Adjustments for increase (decrease) in trade payables, non-current	0	0
Adjustments for increase (decrease) in other current liabilities	0.21	-11.33
Adjustments for increase (decrease) in other non-current liabilities	0	0
Adjustments for depreciation and amortisation expense	0.52	0.57
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0	0
Adjustments for provisions, current	3.24	3.24
Adjustments for provisions, non-current	0	0
Adjustments for other financial liabilities, current	0	14.38
Adjustments for other financial liabilities, non-current	4.41	0
Adjustments for unrealised foreign exchange losses gains	0	0
Adjustments for dividend income	0	0
Adjustments for interest income	0	0
Adjustments for share-based payments	0	0
Adjustments for fair value losses (gains)	0	0
Adjustments for undistributed profits of associates	0	0
Other adjustments for which cash effects are investing or financing cash flow	0	0
Other adjustments to reconcile profit (loss)	0	0
Other adjustments for non-cash items	0	0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0	0
Total adjustments for reconcile profit (loss)	8.10	6.92
Net cash flows from (used in) operations	-0.11	0.04
Dividends received	0	0
Interest paid	0	0
Interest received	0	0
Income taxes paid (refund)	0	0
Other inflows (outflows) of cash	0	0
Net cash flows from (used in) operating activities	-0.11	0.04
Cash flows from used in investing activities		
Cash flows from losing control of subsidiaries or other businesses	0	0
Cash flows used in obtaining control of subsidiaries or other businesses	0	0
Other cash receipts from sales of equity or debt instruments of other entities	0	0
Other cash payments to acquire equity or debt instruments of other entities	0	0
Other cash receipts from sales of interests in joint ventures	0	0
Other cash payments to acquire interests in joint ventures	0	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0	0

Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0	0
Proceeds from sales of property, plant and equipment	0	0
Purchase of property, plant and equipment	0	0
Proceeds from sales of investment property	0	0
Purchase of investment property	0	0
Proceeds from sales of intangible assets	0	0
Purchase of intangible assets	0	0
Proceeds from sales of intangible assets under development	0	0
Purchase of intangible assets under development	0	0
Proceeds from sales of goodwill	0	0
Purchase of goodwill	0	0
Proceeds from biological assets other than bearer plants	0	0
Purchase of biological assets other than bearer plants	0	0
Proceeds from government grants	0	0
Proceeds from sales of other long-term assets	0	0
Cash receipts from repayment of advances and loans made to other parties	0	0
Cash payments for future contracts, forward contracts, option contracts and swapcontracts	0	0
Cash receipts from future contracts, forward contracts, option contracts and swapcontracts	0	0
Dividends received	0	0
Interest received	0	0
Income taxes paid (refund)	0	0
Other inflows (outflows) of cash	0	0
Net cash flows from (used in) investing activities	0	0
Cash flows from used in financing activities		
Proceeds from changes in ownership interests in subsidiaries	0	0
Payments from changes in ownership interests in subsidiaries	0	0
Proceeds from issuing shares	0	0
Proceeds from issuing other equity instruments	0	0
Payments to acquire or redeem entity's shares	0	0
Payments of other equity instruments	0	0
Proceeds from exercise of stock options	0	0
Proceeds from issuing debentures notes bonds etc	0	0
Proceeds from borrowings	0	0
Repayments of borrowings	0	0
Payments of finance lease liabilities	0	0
Payments of lease liabilities	0	0
Dividends paid	0	0
Interest Paid	0	0
Income taxes paid (refund)	0	0
Other inflows (outflows) of cash	0	0
Net cash flows from (used in) financing activities	0	0
Net increase (decrease) in cash and cash equivalents before effect of exchange ratechanges	-0.11	0.04
Effect of exchange rate changes on cash and cash equivalents	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	-0.11	0.04
Cash and cash equivalents cash flow statement at beginning of period	0.18	0.14
Cash and cash equivalents cash flow statement at end of period	0.07	0.18
Notes:		
The above results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 28th May, 2022 The Statutory auditors have conducted the audit of the above financial results and have expressed an unmodified report on the same.		
For Raymed Labs Limited		
<small>Digitally signed by AJAI GOYAL Date: 2022.05.28 16:31:47 +05'30'</small> AJAI GOYAL (Ajai Goyal) Whole time Director DIN: 02636418		
Date: 28.05.2022		
Place: Noida		

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 28.05.2022

The Head-Listing Compliance
BSE Limited,
PhirozeJeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Scrip Code: 531207

Subject: Non Applicability of Disclosure on Related Party Transactions on a consolidated basis under Regulation 23(9) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the half year ended March 31, 2022

Dear Sir,

This has reference to Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, where a company is exempt from compliance with few specified regulations if the listed entity is having paid up equity share capital not exceeding Rs. 10,00,00,000/- (Rupees Ten Crore) and net worth not exceeding Rs. 25,00,00,000/- (Rupees Twenty Five Crore) as on the last date of previous financial year.

Please note that our Company has **Paid up Capital of Rs. 427.35Lakh** only (i.e. less than stipulated limit of Rs.10 Crore) and **Net Worth of Rs. (213.5)Lakh** only (i.e. less than stipulated limit of Rs. 25 Crore) as per the last audited balance sheet as on March 31, 2022.

Therefore, in terms of the aforesaid Regulation i.e. Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015, the Company is not under any obligation to file **Disclosure on Related Party Transactions on a consolidated basis** for the half year ended on March 31, 2022.

We request you to kindly take the above information on your records.

For Raymed Labs Limited

AJAI

Digitally signed
by AJAI GOYAL

GOYAL

Date: 2022.05.28
16:33:21 +05'30'

Ajai Goyal
Whole Time Director
DIN: 02636418

Place: Noida

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, **Website-** www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, **Phone no.** - 0120-2426900, 9412700300

Date: 28.05.2022

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai-400001

Scrip Code: 531207

Subject: Non Applicability of Compliance with Statement of Deviation(s) or Variation(s) as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter ended March 31, 2022

Dear Sir/Madam,

With reference to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the disclosure of Statement of Deviation(s) or Variation(s) under the said regulation is not applicable to the Company.

Kindly take the same in your records.

Thanking You,

Yours Sincerely,

For Raymed Labs Limited

AJAI

GOYAL

Digitally signed by
AJAI GOYAL
Date: 2022.05.28
16:34:01 +05'30'

Ajai Goyal

Whole Time Director

DIN: 02636418

Place: Noida